InhaleGene – Inhalable Precision Gene Therapy for Lung Cancer
0
100%
1st Mar
2023
Gene Construct Design And Synthesis
Join
Gene Construct Design And Synthesis
Background
The problem / challenges: Gene Construct Design And Synthesis

Valuation: £1.0M Design, synthesize, and verify tumor-targeted gene constructs to modulate drug‑resistance pathway in SCLC cells; establish initial assays and QC for construct function. 

Expected valuation at this milestone: $1.4 million
0
100%
Jun
2024
Join
Initial Funding And Grant Secured
Background

Valuation: £1.8M. Raised £450k and secured an Innovate UK non‑dilutive grant supporting in‑vitro program and early delivery workstreams

Expected valuation at this milestone: $2.4 million
0
100%
Jan
2025
Join
siRNA Cocktail Design And Optimization
Background

Valuation: £3.0M. Select, evaluate, and optimize a multi‑siRNA cocktail to modulate tumor microenvironment and drug‑resistance pathways in SCLC cells; confirm knockdown efficacy and specificity.

Expected valuation at this milestone: $4 million
0
70%
May
2025
Join
Nanoparticle Formulation And Optimization Advanced
Background

Valuation: £5.0M. Screen and refine inhalable nanoparticle formulations for siRNA cocktail and tumor-activated DNA construct; demonstrate stability, aerosol performance, and cellular uptake.

Expected valuation at this milestone: $6.7 million
0
30%
Dec
2025
Join
Seed Extension Round Launched Now, Round Closed And Execution Plan
Background

Valuation: £6.5M (post‑money). Close £1.5M raise; lock vendor slots, QA/biostats, and CRO timelines to initiate in‑vivo program.

Expected valuation at this milestone: $8.7 million
0
20%
Mar
2026
Join
Provisional Patent Filed With Data
Background

Valuation: £8.0M. Finalize in‑vitro DNA construct; demonstrate aerosolizable nanoparticle performance; file provisional; begin rolling data submissions to counsel.

Expected valuation at this milestone: $10.7 million
0
0%
Jun
2026
Join
Biodistribution And Tumor Activation Shown
Background

Valuation: £11.0M. Rodent studies show lung deposition, tumor-site activation of DNA construct, and clean acute tolerability; scramble controls behave as expected.

Expected valuation at this milestone: $14.7 million
0
0%
Sep
2026
Join
First Efficacy Signal In Vivo
Background

Valuation: £15.0M. Clinically relevant SCLC model shows tumor-control trend for multi‑siRNA and DNA arms; biomarker plan fixed; compare nebulized inhalation versus systemic delivery.

Expected valuation at this milestone: $20 million
0
0%
Dec
2026
Join
Efficacy Replication And CMC Lite
Background

Valuation: £19.0M. Second cohort reproduces efficacy; batch‑to‑batch nanoparticle reproducibility and release assays; select PCT route; SoC combination feasibility demonstrated.

Expected valuation at this milestone: $25 million
0
0%
Mar
2027
Join
Extended Tolerability And Stability Package
Background

Valuation: £23.0M. GLP‑like rodent tolerability and immunogenicity complete; stability supports IND/CTA planning; regulator question set drafted.

Expected valuation at this milestone: $31 million
0
0%
Jun
2027
Join
Regulatory Alignment And IND Roadmap
Background

Valuation: £27.0M. Receive Scientific Advice/pre‑IND feedback; agreed path to IND/CTA; external KOL validation; partner diligence ready.

Expected valuation at this milestone: $36 million
Suggest a milestone Start a collaboration
Join RS&RS Scientific Ltd's Business Subnetwork
Join Now
Comment:
4000 characters remaining.
Submit
Start a collaboration
Owner:
RS&RS Scientific Ltd
Hero points
Rewards for social and environmental contributions
Earn 50 points - Join now
Collaborations
Engage groups of people to progress creative solutions through community
Add a collaboration
Roadmaps
Show what you’ve done and where you are going- interactively with your stakeholders or the public
Add a Roadmap
PIERS- Public Interactive ESG Roadmaps
Collaborate with the pubic to make better decisions on social, environmental and governance
Solutions
Qualified participants can submit solutions to collaborations for vote by communities. Earn Hero Points or money sponsorship rewards where applicable if your solution receives the most verified, qualifying votes
Roadmaps are a new way to solve challenges with community networks. You can host a collaboration to solve an issue and invite members of other WEN subnetworks or create your own. You can also join collaborations and earn hero points, rewards or in some cases sponsorship.
Participation rules

We’re committed to free and open engagement with the focus on solving a challenge or improving our world through community collaboration and consensus.

So obviously, please keep it civil, but above and beyond that—hosts and/or WeNetwork also reserve the right to remove any posts (and in extreme cases, WeNetwork members) that violate the following basic rules:

  • No marketing or spam. Come on, you know this!
  • No masquerading, by either subjects or participants
    Roadmaps and collaboration can be hosted by third parties, just as long as long as ownership is accurately identified.
    So, for instance, anyone can create a roadmap for JPMorgan as long as they are clear that they are not affiliated with JPMorgan, if that is the case. And no participant may falsely represent themselves as an affiliate, either.
    Users are required to disclose any material conflicts of interest in posts of any type.
  • Relevance to solution
    No “look there’s a squirrel” stuff—stay on topic, relevant, and constructive.
  • Age limit
    You must be 18 to use this site. If you are young, smart and engaged and really want to participate, please contact us for information about obtaining parental permission.
  • Not a complaint site
    Our platform is intended for crowdsourcing solutions. Any post attempting to disparage, defame or otherwise attack any business or individual is subject to removal.
    If you have a specific problem with any organization, including WeNetwork or any of its members, please email team@WeNetwork.app.
  • Qualifications to post a solution
    Anyone is welcome to post a civil, relevant and constructive comment. In most cases, though, posting a formal solution requires a minimum level of hero points. Solutions posted by anyone who doesn’t have enough hero points will be forwarded to the host for consideration.
By using this site you agree to abide by the rules set out by WeNetwork and any collaboration host.